Antares Pharma — Investor Presentation (September 2019)
22 slides from Antares Pharma's investor presentation, Sep 10, 2019
Slide 1: Antares Pharma Investors' Update September 2019
Antares Pharma Investors’ Update September 2019 EX 99.1
Slide 2: Forward-looking statements
This presentation contains forward-looking statements within the meaning of the safe harbour provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those des
Slide 3: Antares Pharma Overview
Antares Pharma is an innovative leader in self-administered injection technology Five products utilizing FDA-approved Antares devices were commercialized in the past five years; three in 2018 alone XYOSTED® (testosterone enanthate) Makena® (hydroxyprogesterone) Generic EpiPen® (epinephrine) All are
Slide 4: Continued dramatic shift toward growth in product revenue
Continued dramatic shift toward growth in product revenue Q219 - $20.6M in product revenue – an 86% increase compared to the same period one year ago Commercialized proprietary products: XYOSTED® and OTREXUP®: $9.0M Partnered products: Teva EpiPen Teva Sumatriptan AMAG Makena® Needle Free Antares Ph
Slide 5: Antares Pharma Proprietary Commercial Products
Antares Pharma Proprietary Commercial Products September 2019
Slide 6: An innovative way to deliver testosterone replacement therapy
An innovative way to deliver testosterone (T) replacement therapy 98.5% of phase-3 study XYOSTED® patients achieved testosterone levels in the normal, physiologic range A narrow peak-to-trough ratio of 1.8 means T levels stay steady T Levels maintained for as long as the patient stays on therapy* St
Slide 7: Ctrough Stable For Weeks
Ctrough Stable For 52 Weeks 6 12 18 26 38 52 Week 1, pre-dose Mean Ctrough (ng/dL) over 52 week “003” study Green lines represent the defined range of 300 – 1100 ng/dL ………….. Baseline QST-13-003 treatment regimen demonstrated a mean steady state concentration of testosterone of 553.3 ± 127.3 ng/dL a
Slide 8: Multiple Channels Directed at Key Targets
Trial Experience Multiple Channels Directed at Key Targets Multi-channeling campaign targets physicians and patients through digital, social, enduring, and live platforms that drive awareness, prescription generation, and prescription fulfillment Access program further aids prescription fulfillment
Slide 9: XYOSTED Growth Since Launch
More than 20,000* XYOSTED® TRx’s to date written by ~2,800 different physicians More than 10,000 patients prescribed XYOSTED® since launch XYOSTED® Growth Since Launch
Slide 10: Broad Utilization Across all TRT Specialties
Commercial Experience Broad Utilization Across all TRT Specialties
Slide 11: Antares Commercial Products: OTREXUP and generic sumatriptan
Commercial Experience Antares Commercial Products OTREXUP® (methotrexate) for injection and generic sumatriptan generated combined revenue of $29 million in 2018 Q2 2019 combined revenue was $7.3 million 2019 year-to-date combined revenue - $14.9 million
Slide 12: Antares Pharma Partnered Commercial Products
Antares Pharma Partnered Commercial Products September 2019
Slide 13: Teva's Generic EpiPen
Commercial Experience Teva’s Generic EpiPen Teva’s generic EpiPen® was approved by FDA as therapeutically equivalent to Mylan’s EpiPen® and is fully substitutable at the pharmacy Antares receives cost plus margin on all devices sold to Teva plus mid-to-high, single-digit royalties on in-market sales
Slide 14: Generic EpiPen Monthly Prescription Trends
Commercial Experience Generic EpiPen® Monthly Prescription Trends
Slide 15: Makena hydroxyprogesterone caproate injection
Commercial Experience Makena® hydroxyprogesterone caproate injection Makena® is to used to reduce the risk of pre-term birth in certain at-risk women Provides patients with efficient, discreet, and user-friendly administration AMAG/Antares collaboration began in 2014 Antares receives cost plus produ
Slide 16: Antares Pharma Development Pipeline
Antares Pharma Development Pipeline September 2019
Slide 17: Antares Pharma Pipeline
Commercial Experience Antares Pharma Pipeline Product Preclinical Phase 1 Phase 2 Phase 3 Marketed Antares Proprietary and Partnered Products Teriparatide (Teva) Exenatide (Teva) ATRS-1701 Neurology (Antares) Methotrexate for Ectopic Pregnancy (Antares) Orphan Status Undisclosed Rescue Pen (Pfizer)
Slide 18: Antares Pharma Q2 2019 Financial Results
Antares Pharma Q2 2019 Financial Results September 2019
Slide 19: Antares Pharma Q2 and YTD 2019
Commercial Experience Antares Pharma Q2 and YTD 2019 Three Months Ended June 30 Increase Six Months Ended June 30 Increase 2019 2018 (Decrease) 2019 2018 (Decrease) Total Revenue $ 28,433 $ 14,162 101% $ 51,719 $ 26,865 93% Cost of Revenue 12,441 6,960 79% 23,387 14,146 65% Gross Profit 15,992 7,202
Slide 20: 5-year Growth and 2019 Projection
+17% vs. 2017 +57-73% vs. 2018* 5-year Growth and 2019 Projection Projected CAGR of 31.7% * Percent increase based on revised 2019 guidance +72% vs. 2014 +14% vs. 2015
Slide 21: Antares Pharma: 5 Potential Catalysts
Continued XYOSTED® prescription growth and adoption Continued generic EpiPen® and EpiPen® Jr. prescription growth and adoption Continued contribution from the Makena® subcutaneous hydroxyprogesterone auto-injector Potential FDA approval and launch of Teva’s generic teriparatide (Forteo®) for patient
Slide 22: Thank you / Questions
antares pharma Thank you Questions making medicines better fool
Antares Pharma — Investor Presentation (September 2019) on 6ix